{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:56:42Z","timestamp":1776808602220,"version":"3.51.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.htct.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:03:34Z","timestamp":1727287414000},"page":"S250-S256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S6","title":["Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method"],"prefix":"10.1016","volume":"46","author":[{"given":"Astrid","family":"Pavlovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9090-8234","authenticated-orcid":false,"given":"Juan Ignacio Garcia","family":"Altuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Fiad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Kurgansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-8190","authenticated-orcid":false,"given":"Fernando","family":"Warley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Negri Aranguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1016\/j.htct.2024.07.007_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/1097-0142(19950101)75:1+<357::AID-CNCR2820751318>3.0.CO;2-A","article-title":"Hodgkin's disease","volume":"75","author":"Medeiros","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.htct.2024.07.007_bib0002","unstructured":"American Society of Clinical Oncology. Lymphoma - Hodgkin: statistics. 2022. Available at: https:\/\/www.cancer.net\/cancer-types\/lymphoma-hodgkin\/statistics"},{"issue":"30","key":"10.1016\/j.htct.2024.07.007_bib0003","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.htct.2024.07.007_bib0004","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2024.07.007_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2024.07.007_bib0006","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0007","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.15838","article-title":"PET -adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH -05 trial","volume":"185","author":"Pavlovsky","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2024.07.007_bib0008","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/01.HS9.0000847192.97515.16","article-title":"P1081: pet-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial","volume":"6","author":"Pavlovsky","year":"2022","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.htct.2024.07.007_bib0009","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.htct.2024.07.007_bib0010","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2024.07.007_bib0011","volume":"Version 2.2023","year":"2022"},{"key":"10.1016\/j.htct.2024.07.007_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1752-4458-4-33","article-title":"Where there is no evidence: use of expert consensus methods to fill the evidence gap in low-income countries and cultural minorities","volume":"4","author":"Minas","year":"2010","journal-title":"Int J Ment Health Syst"},{"issue":"6","key":"10.1016\/j.htct.2024.07.007_bib0013","doi-asserted-by":"crossref","first-page":"e20476","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.htct.2024.07.007_bib0014","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2648.2003.02537.x","article-title":"The Delphi technique: myths and realities","volume":"41","author":"Powell","year":"2003","journal-title":"J Adv Nurs"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0015","first-page":"e441","article-title":"[Clinical guidelines for the managment of intestinal failure secondary to pediatric short bowel syndrome]","volume":"119","author":"Fern\u00e1ndez","year":"2021","journal-title":"Arch Argent Pediatr"},{"issue":"2","key":"10.1016\/j.htct.2024.07.007_bib0016","first-page":"94","article-title":"Recommendations for the follow-up of children with leg length discrepancy: expert consensus","volume":"117","author":"Caino","year":"2019","journal-title":"Arch Argent Pediatr"},{"issue":"15","key":"10.1016\/j.htct.2024.07.007_bib0017","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.htct.2024.07.007_bib0018","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2024.07.007_bib0019","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.2967\/jnumed.108.057190","article-title":"PET\/CT for therapy response assessment in lymphoma","volume":"50","author":"Hutchings","year":"2009","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0021","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdp519","article-title":"Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET\/CT for follow-up?","volume":"21","author":"Petrausch","year":"2010","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.htct.2024.07.007_bib0022","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00277-019-03889-3","article-title":"Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study","volume":"99","author":"Rigacci","year":"2020","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.htct.2024.07.007_bib0023","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[ 18 F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2024.07.007_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.htct.2024.07.007_bib0025","first-page":"603","article-title":"Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy","volume":"47","author":"Engles","year":"2006","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0026","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.htct.2024.07.007_bib0027","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response\u2013adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0028","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00259-003-1120-6","article-title":"[18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?","volume":"30","author":"Spaepen","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.htct.2024.07.007_bib0029","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.htct.2024.07.007_bib0030","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.htct.2024.07.007_bib0031","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.2838","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study","volume":"39","author":"Hutchings","year":"2021","journal-title":"Hematol Oncol"},{"issue":"S22","key":"10.1016\/j.htct.2024.07.007_bib0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.COT.0000903872.68662.93","article-title":"ECHELON-1: evaluating brentuximab vedotin in Hodgkin's lymphoma","volume":"44","author":"Simoneaux","year":"2022","journal-title":"Oncol Times"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137924025537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137924025537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:07:15Z","timestamp":1737976035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137924025537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"alternative-id":["S2531137924025537"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2024.07.007","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}